Literatur
AIM – International Association of Mutual Benefit Societies (2016). Adaptive pathways: Why are we cautious? https://www.aim-mutual.org/mediaroom/adaptive-pathways-why-are-we-cautious/?lang=de. Zugegriffen 17.10.2017.
Banzi R, Gerardi C, Bertele' V, Garattini S (2015). Approvals of drugs with uncertain benefit-risk profiles in Europe. Eur J Intern Med. Oct;26(8):572-84. doi: 10.1016/j.ejim.2015.08.008. Epub 2015 Sep.
Banzi R, Gerardi C, Bertele' V, Garattini S (2017). Conditional approval of medicines by the EMA. BMJ May 2;357:j2062. doi: 10.1136/bmj.j2062.
BEUC - The European Consumer Organisation (2016). A fast-track approval for new medicines – patient safety at risk? BEUC position on adaptive pathways. http://www.beuc.eu/publications/beuc-x-2016-066_fca_ipa_beuc_position_paper_on_adaptive_pathways.pdf. Zugegriffen 17.10.2017.
BUKO Pharma-Kampagne (2016). Pilotprojekt gescheitert –weiter so? EMA hält an Schnellzulassung fest. Pharmabrief Nr. 7, Sp./Okt. 2016. http://www.bukopharma.de/uploads/file/Pharma-Brief/Phbf2016_07.pdf. Zugegriffen 17.10.2017.
Cattarin F (2016). When drug approval is quick, it should not be dirty. BEUC-The European Consumer Organisation. http://www.beuc.eu/blog/when-drug-approval-is-quick-it-should-not-be-dirty/. Zugegriffen 17.10.2017.
Collier R (2011). Bye, bye blockbusters, hello niche busters. CMAJ. 2011 Aug 9;183(11):E697-8. doi: 10.1503/cmaj.109-3874. Epub 2011 Jun 20.
Davis C, Lexchin J, Jefferson T, Gøtzsche P, McKee M (2016). "Adaptive pathways" to drug authorisation: adapting to industry? BMJ Aug 16;354:i4437. doi: 10.1136/bmj.i4437.
Dolgin E (2010). Big pharma moves from 'blockbusters' to 'niche busters'. Nat Med. Aug;16(8):837. doi: 10.1038/nm0810-837a.
Ermisch M, Bucsics A, Vella Bonanno P, Arickx F, Bybau A, Bochenek T, van de Casteele M, Diogene E, Fürst J, Garuolienė K, van der Graaff M, Gulbinovič J, Haycox A, Jones J, Joppi R, Laius O, Langner I, Martin AP, Markovic-Pekovic V, McCullagh L, Magnusson E, Nilsen E, Selke G, Sermet C, Simoens S, Sauermann R, Schuurman A, Ramos R, Vlahovic-Palcevski V, Zara C, Godman B. (2016). Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. Front Pharmacol. 2016; 7: 305. doi: 10.3389/fphar.2016.00305.
European Medicines Agency (2016a). Final report on the adaptive pathways pilot http://www.ema.europa.eu/docs/en_GB/document_library/Report/2016/08/WC500211526.pdf. Zugegriffen 17.10.2017.
European Medicines Agency (2016b). Adaptive Pathways Workshop. Report on a meeting with stakeholders held at EMA on Thursday 8 December 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/02/WC500222153.pdf. Zugegriffen 17.10.2017.
European Medicines Agency (2017). Annual Report 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Annual_report/2017/05/WC500227334.pdf. Zugegriffen 17.10.2017.
Fain K et al (2013). The Food and Drug Administration Amendments Act and postmarketing commitments. JAMA. 310(2):202-4. doi: 10.1001/jama.2013.7900.
Finance and NHS /Medicines, Pharmacy and Industry Group/17080 (2013). The Pharmaceutical Price Regulation Scheme 2014. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/621983/2014_PPRS_Scheme.pdf. Zugegriffen 17.10.2017.
Frieden TR (2017). Evidence for Health Decision Making - Beyond Randomized, Controlled Trials. N Engl J Med. 2017 Aug 3;377(5):465-475. doi: 10.1056/NEJMra1614394.
GKV-Spitzenverband (2017). Positionspapier des GKV-Spitzenverbandes für die 19. Legislaturperiode 2017–2021. https://www.gkv-spitzenverband.de/media/dokumente/presse/publikationen/Positionspapier_neue_Legislaturperiode_2017-2021_barrierefrei_a.pdf. Zugegriffen 17.10.2017.
Health Action International et al. (2015). Adaptive licensing or adaptive pathways: Deregulation under the guise of earlier access. Joint briefing paper https://ec.europa.eu/health//sites/health/files/files/committee/stamp/2015-10_stamp3/3c_prescrire_position_paper.pdf. Zugegriffen 17.10.2017.
HTA.de - Verein zur Förderung der Technologiebewertung im Gesundheitswesen (Health Technology Assessment) (2016). Keine Absenkung von Standards bei der Arzneimittelzulassung auf Kosten von Patienten und Solidargemeinschaft. http://www.health-technology-assessment.de/PM_Adaptive%20Pathways_2016-04-13.pdf. Zugegriffen 06.09.2017.
IQWiG (2016). Adaptive Pathways: EMA lässt offene Fragen weiter unbeantwortet. Pressemitteilung vom 09.08.2016. https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/adaptive-pathways-ema-lasst-offene-fragen-weiter-unbeantwortet.7492.html. Zugegriffen 17.10.2017.
Joppi R, Gerardi C, Bertele' V, Garattini S. (2016). Letting post-marketing bridge the evidence gap: the case of orphan drugs. BMJ. Jun 22;353:i2978. doi: 10.1136/bmj.i2978.
Kesselheim AS, Wang B, Franklin JM, Darrow JJ (2015). Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ. 2015 Sep 23;351:h4633. doi: 10.1136/bmj.h4633.
Kumar Kakkar A, Dahiya N. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space. Drug Dev Res. 2014 Jun;75(4):231-4. doi: 10.1002/ddr.21176. Epub 2014 May 14.
Kim C, Prasad V (2015). Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Intern Med Dec;175(12):1992-4. doi: 10.1001/jamainternmed.2015.5868.
Ludwig WD (2017a). Zulassungsverfahren für neue Arzneimittel in Europa. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J (Hrsg.). Arzneiverordnungsreport 2017. Springer Verlag. S. 33-53.
Ludwig WD (2017b). Nutzen und Risiken von Orphan Drugs und Adaptive Pathways für Patient, Arzt und Hersteller. In: Grandt D, Schubert I (Hrsg.). BARMER Arzneimittelreport 2017. Schriftenreihe zur Gesundheitsanalyse. Band 3. S 232-245. https://www.barmer.de/blob/121882/d55553c9f2ee27c1943ce117014511de/data/dl-barmer-arzneimittelreport-2017.pdf. Zugegriffen 17.10.2017.
McKee AE, Farrell AT, Pazdur R, Woodcock J (2010). The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. Oncologist.;15 Suppl 1:13-8. doi: 10.1634/theoncologist.2010-S1-13.
Naci H, Smalley KR, Kesselheim AS (2017).Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration. JAMA Aug 15;318(7):626-636. doi: 10.1001/jama.2017.9415.
Natsis Y (2016a). Scientists voice concerns about adaptive pathways. https://epha.org/scientists-voice-concerns-about-adaptive-pathways. Zugegriffen 17.10.2017.
Natsis Y (2016b). EPHA Briefing. Will fast-tracking medicines improve affordability? epha. https://epha.org/epha-briefing-will-fast-tracking-medicines-improve-affordability. Zugegriffen 17.10.2017.
Natsis Y (2017). The Top 5 Issues in Medicines Policy for 2017. European Public Health Alliance (epha). https://epha.org/the-top-5-issues-in-medicines-policy-for-2017/. Zugegriffen 17.10.2017.
Navarria A, Drago V, Gozzo L, Longo L, Mansueto S, Pignataro G, Drago F (2015). Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure. Value Health Jan;18(1):131-6. doi: 10.1016/j.jval.2014.09.007. Epub 2014 Nov 11.
NHS Scotland. Patient Access Scheme (PAS) Guidance V4.0. https://www.scottishmedicines.org.uk/media/3050/nhsscotland-pas-guidance.pdf. Zugegriffen 17.10.2017.
Pauwels K, Huys I, Vogler S, Casteels M, Simoens S (2017). Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. Front Pharmacol. Apr 4;8:171. doi: 10.3389/fphar.2017.00171. eCollection 2017.
Pease AM, Krumholz HM, Downing NS, Aminawung JA, Shah ND, Ross J (2017). Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review BMJ May 3;357:j1680. doi: 10.1136/bmj.j1680.
Prasad V, Mailankody S (2017). Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. JAMA Intern Med. Sep 11. doi: 10.1001/jamainternmed.2017.3601. [Epub ahead of print].
Prescrire (2016). “Adaptive pathways”: EMA’ s dangerous plan. Rev Prescrire April 2016; 36 (390): 293-299 http://english.prescrire.org/en/81/168/52124/0/NewsDetails.aspx. Zugegriffen 17.10.2017.
Rat der EU (2016). Schlussfolgerungen des Rates zur Verstärkung der Ausgewogenheit der Arzneimittelsysteme in der EU und ihren Mitgliedstaaten. Pressemitteilung 350/16 vom 17.06.2016. http://www.consilium.europa.eu/press-releases-pdf/2016/6/47244642812_de.pdf. Zugegriffen 17.10.2017.
Scannell J (2015). Four Reasons Drugs Are Expensive, Of Which Two Are False. Forbes Media. https://www.forbes.com/sites/matthewherper/2015/10/13/four-reasons-drugs-are-expensive-of-which-two-are-false/2/#307ee29b6522. Zugegriffen 17.10.2017.
Schwabe U, Ludwig WD (2017). Arzneiverordnungen 2016 im Überblick. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J (Hrsg.). Arzneiverordnungsreport 2017. Springer Verlag. S. 21.
Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM (2016). Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med. 2016 Dec 8;375(23):2293-2297.
Voelker R (2017). Faster Orphan Drug Decisions. JAMA Aug 15;318(7):604. doi: 10.1001/jama.2017.10130.
Wild C, Zechmeister-Koss I, Vogler S (2017). Risk-sharing Schemes und weitere Managed-Entry Agreements: Sind vertrauliche Abkommen zielführend oder kontraproduktiv? Ludwig-Boltzman-Institut - Health Technology Assessment. Newsletter Februar 2017 | Nr. 154. http://hta.lbg.ac.at/page/risk-sharing-schemes-und-weitere-managed-entry-agreements-sind-vertrauliche-abkommen-zielfuehrend-oder-kontraproduktiv/de. Zugegriffen 17.10.2017.
Zentner A, Haas A (2016a): Prinzip Hoffnung versus Prinzip Risiko - Folgen des beschleunigten Marktzugangs von Arzneimitteln. Schriftenreihe Plattform zur Nutzenbewertung Heft 3. Springer. https://www.aerztezeitung.de/includes/pdf/plattform_zur_nutzenbewertung/3/adaptive_pathways_-_chancen_und_risiken.pdf. Zugegriffen 17.10.2017.
Zentner A, Haas A (2016b): Adaptive Pathways - Was würde ein beschleunigter Marktzugang von Arzneimitteln in Deutschland bedeuten? Gesundheits- und Sozialpolitik 70 (1): 59–66.